scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Acquired by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC raised its position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 25.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 621,665 shares of the company's stock after purchasing an additional 124,438 shares during the quarter. Rice Hall James & Associates LLC owned 1.72% of scPharmaceuticals worth $2,835,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. King Luther Capital Management Corp raised its holdings in shares of scPharmaceuticals by 51.8% during the second quarter. King Luther Capital Management Corp now owns 2,205,140 shares of the company's stock worth $9,592,000 after purchasing an additional 752,005 shares during the last quarter. Bank of Montreal Can acquired a new position in shares of scPharmaceuticals in the 2nd quarter valued at about $1,544,000. AIGH Capital Management LLC boosted its stake in shares of scPharmaceuticals by 3.4% in the second quarter. AIGH Capital Management LLC now owns 3,504,365 shares of the company's stock worth $15,244,000 after buying an additional 115,206 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in scPharmaceuticals by 266.7% during the second quarter. Assenagon Asset Management S.A. now owns 72,692 shares of the company's stock worth $316,000 after acquiring an additional 52,870 shares during the period. Finally, Virtu Financial LLC purchased a new position in scPharmaceuticals during the first quarter valued at approximately $90,000. 89.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "buy" rating and issued a $18.00 price objective on shares of scPharmaceuticals in a research report on Monday, August 19th.

scPharmaceuticals Stock Performance

SCPH stock traded down $0.08 during midday trading on Friday, hitting $4.07. 146,602 shares of the stock traded hands, compared to its average volume of 245,137. scPharmaceuticals Inc. has a 1-year low of $3.24 and a 1-year high of $6.71. The company has a debt-to-equity ratio of 4.32, a current ratio of 4.84 and a quick ratio of 3.66. The stock's fifty day simple moving average is $4.68 and its 200-day simple moving average is $4.52. The firm has a market cap of $203.62 million, a P/E ratio of -2.61 and a beta of 0.15.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.44) EPS for the quarter, meeting analysts' consensus estimates of ($0.44). scPharmaceuticals had a negative return on equity of 201.84% and a negative net margin of 252.18%. The firm had revenue of $8.05 million for the quarter, compared to analysts' expectations of $8.04 million. On average, analysts expect that scPharmaceuticals Inc. will post -1.34 earnings per share for the current year.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.